Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Jake Dunning, Honorary Visiting Research Fellow in Tropical Medicine (ERGO) and Deputy Programme Director for High Consequence Infectious Diseases, NHS England, is appointed MBE for services to Clinical Research. Dr Dunning led clinical trials during the terrible Ebola epidemic in West Africa.

Jake Dunning
Dr Jake Dunning, Honorary Visiting Research Fellow at the Centre for Tropical Medicine and Global Health, has been awarded an MBE in the New Year's Honours list. The award recognises his services to clinical research, particularly his contributions to Ebola research efforts. Jake joined the Epidemic diseases Research Group Oxford (ERGO) in October 2014, as part of the RAPIDE trial team studying potential treatments for Ebola virus disease in West Africa. The trials, led by Prof Peter Horby, evaluated two candidate drugs at Ebola treatment centres in Liberia and Sierra Leone. Jake was the Field Lead for the trials, based in West Africa, and worked with over 40 researchers from 10 countries, including doctors and nurses from the affected countries.
Following completion of the trials in 2015, Jake moved to a new full time post as Consultant in Infectious Diseases at the National Infection Service, Public Health England. However, he continues to work with ERGO on preparedness and response activities for outbreak research. Additionally, Jake is the NHS England Deputy Programme Director for High Consequence Infectious Diseases, which includes diseases such as viral haemorrhagic fever, avian influenza, and pneumonic plague. He also practises clinical infectious diseases at the Royal Free Hospital, London. Along with other trial team members, Jake received a British Government Ebola Service Medal in 2015, and his international colleagues were recognised with the award of Oxford Ebola service medals.
On receiving his award, Jake said "I am very grateful to have received this honour, mindful that I was part of a brilliant and dedicated team. Without the extraordinary support of colleagues in the field and in Oxford, these unique and very challenging trials would not have happened. We are now applying the skills and lessons learned to improving outbreak preparedness, response and research activities for high consequence infections, both overseas and in the UK. I am indebted to Peter Horby and the Centre, for having provided me with such an amazing opportunity.

Read more »

Similar stories

Risks of serious adverse events following treatment for visceral leishmaniasis

OCGHR Publication Research

This large-scale systematic review and meta-analysis aimed to collate all reported serious adverse events in visceral leishmaniasis clinical trials and quantify the incidence of mortality during the first 30 days of therapy. The analyses, which included clinical data from more than 35,000 patients, found that mortality following treatment was an extremely rare event and serious adverse events following treatments were poorly reported.

The RECOVERY Trial: One year on

OCGHR Research

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial was officially launched on 23 March 2020. It is the world's largest COVID-19 drug trial. Thanks to the ground-breaking work of RECOVERY, clinicians treating patients hospitalised with severe COVID-19 now have two treatments that are known to improve survival.

Researchers call for access to Ivermectin for young children

OCGHR Publication Research

Millions of children weighing less than 15kg are currently denied access to Ivermectin treatment due to insufficient safety data being available to support a change to the current label indication. The WorldWide Antimalarial Resistance Network’s new meta-analysis provides evidence that supports removing this barrier and improving treatment equity.

Gender imbalance in visceral leishmaniasis clinical trials

OCGHR Publication Research

Researchers have found that despite an ongoing trend for a decreasing proportion of males being enrolled in antileishmanial therapeutic efficacy trials over time, there are still 1.8 times as many males as females involved in clinical trials. A new systematic review and meta-analysis suggests that existing knowledge on drug efficacy is derived from a study population that is heavily skewed towards adult males. At the same time, substantially less is known about the optimal treatment response in female patients.

New report highlights growing concern of vaccine falsification

MORU OCGHR

The Medicine Quality Research Group has published a new Medical Product Quality Report focussing on increasing issues around substandard and falsified (SF) COVID-19 vaccines. With the implementation of the key innovations of COVID-19 vaccines, there have been growing numbers of reports of SF vaccines in the public domain. Given the vital role they will play in ending the pandemic and protecting the global population but severe issues with equitable access, SF vaccines are highly likely to be a growing problem.

RECOVERY trial closes recruitment to colchicine treatment for patients hospitalised with COVID-19

OCGHR Research

Established to test a range of potential treatments for COVID-19, the RECOVERY trial has included a comparison of colchicine, an anti-inflammatory drug that is commonly used to treat gout, vs. usual care alone. There has been no convincing evidence of the effect of colchicine on clinical outcomes in patients admitted to hospital with COVID-19, and recruitment to the colchicine arm of the RECOVERY trial has now closed. Recruitment to all other treatment arms – aspirin, baricitinib, Regeneron’s antibody cocktail, and dimethyl fumarate – continues as planned.